| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NAD-dependent protein deacetylase sirtuin-7, 351-, Regulatory protein SIR2 homolog 7, SIR2-like protein 7, SIRT7, SIR2L7 |
| Entrez GeneID | 51547 |
| WB Predicted band size | 44.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This SIRT7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 331-360 amino acids from the C-terminal region of human SIRT7. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于SIRT7抗体的3篇代表性文献，简要总结如下：
1. **"SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation"**
*作者：Barber, M.F. et al.*
**摘要**：研究通过SIRT7抗体(ChIP和Western blot验证)发现SIRT7通过去乙酰化组蛋白H3K18调控致癌基因稳定性，其缺失抑制癌细胞增殖，提示其在肿瘤发生中的关键作用。
2. **"SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription"**
*作者：Chen, S. et al.*
**摘要**：利用SIRT7抗体(免疫沉淀和免疫荧光)揭示SIRT7通过去乙酰化CDK9激活RNA聚合酶II，调控基因转录延伸，影响细胞应激反应和代谢平衡。
3. **"SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis"**
*作者：Tang, X. et al.*
**摘要**：通过免疫组化(SIRT7抗体)分析临床样本，发现SIRT7低表达与乳腺癌转移相关，其通过抑制TGF-β/Smad信号通路阻止上皮-间质转化(EMT)，提示其抑癌功能。
4. **"SIRT7 suppresses mitochondrial apoptosis by deacetylating and stabilizing Ku70"**
*作者：Wang, L. et al.*
**摘要**：研究使用SIRT7抗体(Western blot和共聚焦显微镜)证明SIRT7通过去乙酰化Ku70抑制线粒体凋亡通路，维持细胞存活，为癌症治疗提供潜在靶点。
这些文献均通过SIRT7抗体验证蛋白表达或定位，并探讨其在基因调控、肿瘤及细胞凋亡中的机制。如需具体期刊信息或年份，可进一步补充检索。
Sirtuin 7 (SIRT7) is a member of the sirtuin family of NAD⁺-dependent deacylases, which play critical roles in regulating cellular processes such as genome stability, metabolism, stress response, and aging. Located predominantly in the nucleolus, SIRT7 is unique among sirtuins for its involvement in ribosomal RNA (rRNA) transcription, chromatin remodeling, and DNA repair. It catalyzes the deacetylation of histone H3 at lysine 18 (H3K18ac) and interacts with non-histone targets, including transcription factors and RNA polymerase I, to modulate transcriptional activity. Studies link SIRT7 to lifespan regulation, cancer progression (acting as both oncogene and tumor suppressor depending on context), and metabolic diseases, highlighting its dual roles in health and disease.
SIRT7 antibodies are essential tools for investigating its expression, localization, and molecular interactions. These antibodies are widely used in techniques like Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and immunohistochemistry. Due to sequence homology among sirtuin family members, antibody specificity is a key consideration. High-quality SIRT7 antibodies are validated using knockout cell lines or tissues to ensure minimal cross-reactivity. Commercial antibodies often target epitopes within the N-terminal or catalytic domains. Recent research employs SIRT7 antibodies to explore its roles in aging-related pathologies, cancer metabolism, and cardioprotection, underscoring its therapeutic potential. However, variability in antibody performance across experimental conditions necessitates careful optimization in different applications.
×
